Sprue-like Enteropathy Associated with Olmesartan

Amanda K. Cartee, Joseph A. Murray

Research output: Contribution to journalReview articlepeer-review


Olmesartan-associated enteropathy (OAE) is a newly described condition reported in several case series in which patients taking olmesartan developed diarrhea, nausea, vomiting, dehydration, and weight loss. Although the symptoms and histologic findings of small-bowel enteropathy resembled severe celiac disease, laboratory work and the lack of response to a gluten-free diet challenged that diagnosis. The injury extended beyond the small bowel, with evidence of lymphocytic/collagenous gastritis and/or colitis in a substantial subset of patients. After a thorough diagnostic evaluation including consideration of alternate diagnoses, and resistance to a variety of treatments, a common thread became apparent: that all affected patients were taking olmesartan. Once this connection was recognized and the medication was suspended, symptoms would improve and the enteropathy healed. Some patients required corticosteroids particularly budesonide (a topically potent steroid) to achieve remission. There remains a gap in knowledge regarding the predisposing factors and mechanism of action.

Original languageEnglish (US)
Article number420
Pages (from-to)1-8
Number of pages8
JournalCurrent Cardiovascular Risk Reports
Issue number12
StatePublished - Sep 30 2014


  • Diarrhea
  • Enteropathy
  • Olmesartan

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Sprue-like Enteropathy Associated with Olmesartan'. Together they form a unique fingerprint.

Cite this